microangiopathy


Also found in: Encyclopedia, Wikipedia.

microangiopathy

 [mi″kro-an″je-op´ah-the]
a disorder involving the small blood vessels. adj., adj microangiopath´ic.
thrombotic microangiopathy formation of thrombi in the arterioles and capillaries; proposed name for a syndrome that would include both thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

cap·il·la·rop·a·thy

(kap'i-lă-rop'ă-thē),
Any disease of the capillaries, often applied to vascular changes in diabetes mellitus.
Synonym(s): microangiopathy
[capillary + G. pathos, disease]

microangiopathy

Any defect of very small blood vessels, usually capillaries, which is most common in diabetes, especially if poorly controlled. Despite thickening of the vascular basement membranes by a hyaline-like material, which corresponds to advanced glycosylation end products (AGEs), the vessels are leaky and allow transvascular passage of plasma proteins. AGEs or advanced diabetic microangiopathy-induced ischaemia directly impacts on the retina, the kidney and the peripheral nerves.

microangiopathy

Vascular disease Any defect of very small blood vessels, usually capillaries, which is most common in DM. See Diabetic microangiopathy.

cap·il·la·rop·a·thy

(kap'i-lă-rop'ă-thē)
Any disease of the capillaries, often applied to vascular changes in diabetes mellitus.
Synonym(s): microangiopathy.
[capillary + G. pathos, disease]

cap·il·la·rop·a·thy

(kap'i-lă-rop'ă-thē)
Any disease of the capillaries.
Synonym(s): microangiopathy.
[capillary + G. pathos, disease]
References in periodicals archive ?
Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA).
The association between paraoxonase 1 activity and the susceptibilities of diabetes mellitus, diabetic macroangiopathy and diabetic microangiopathy. J Cell Mol Med.
The initial presentation of hematuria, thrombocytopenia, and renal failure raised the flag for a thrombotic microangiopathy (TMA), namely, hemolytic-uremic syndrome (HUS), a well-described side effect [4] of VEGF inhibition.
In September 2018, Akari announced in relation to treatment variables that in the first two patients treated with Coversin as part of a U.K.-named patient program, it had observed a rapid reduction of the markers of complement activation as well as normalization of markers that are elevated in thrombotic microangiopathy (TMA).
Pulmonary capillary network may be affected by microangiopathy leading to thickening of basement membrane, affecting the diffusion of gases across respiratory membrane.
In addition, factors such as obesity, high blood pressure, smoking, hypercholesterolemia and dyslipidemia can cause microangiopathy. In macroangiopathy, other risk factors that may cause microangiopathy come to the fore rather than high blood sugar.
Thrombotic microangiopathy (TMA) is usually hereditary and due to acquired causes that lead to severe a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) deficiency.
Our main hypothesis remained a thrombotic microangiopathy (TMA) despite the absence of schistocytes on repeated blood tests.
Keywords: Pakistan Thrombotic microangiopathy, Plasmapheresis, TTP.
Thrombotic microangiopathy (TMA) which is the hallmark of APSN was detected in the repeat biopsy in two patients Change in the histological class was frequent and was seen in 12 out of the 15 patients while patients with proliferative LN class switching to non-proliferative class was rare.
Drug-induced thrombotic microangiopathy (DITMA) with monoclonal antibodies is rare.